Halozyme Therapeutics Inc. Stock
There is an upward development for Halozyme Therapeutics Inc. compared to yesterday, with an increase of €0.54 (1.020%).
With 21 Buy predictions and 2 Sell predictions Halozyme Therapeutics Inc. is one of the favorites of our community.
With a target price of 67 € there is a positive potential of 26.42% for Halozyme Therapeutics Inc. compared to the current price of 53.0 €.
Our community identified positive and negative aspects for Halozyme Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Halozyme Therapeutics Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
B****
?
S********** s********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | 1.020% | -2.574% | -12.077% | 15.872% | 15.974% | -3.267% | 53.712% |
| Ironwood Pharmaceuticals | -2.550% | 4.795% | 12.500% | -7.273% | -27.143% | -73.689% | -69.091% |
| Novocure Ltd | -1.160% | 9.135% | 16.554% | -64.364% | -61.023% | -84.072% | -91.840% |
| Iovance Biotherapeutics Inc. | 0.650% | -0.393% | -12.191% | -74.842% | -72.809% | -71.057% | -95.462% |
Comments
Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for HALO provided by MarketBeat
News
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
Over the last three months, the S&P 500 healthcare sector has risen 13%, compared to the broader S&P 500 index's 7% increase.
However, one stock that hasn't matched its sector's returns is Halozyme
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look
On November 5, 2025, Renaissance Group LLC initiated a new position in Halozyme Therapeutics (NASDAQ:HALO), acquiring 478,735 shares for an estimated $35.11 million, according to a recent SEC
Halozyme (HALO) Q2 EPS Jumps 69%
Halozyme Therapeutics (NASDAQ:HALO), a biotechnology company specializing in drug delivery innovations, released its second-quarter 2025 results on August 5, 2025. The quarter’s headline is